Stevanato Group Spa ( (STVN) ) has released its Q1 earnings. Here is a breakdown of the information Stevanato Group Spa presented to its investors.
Stevanato Group S.p.A., a prominent player in the pharmaceutical, biotechnology, and life sciences sectors, specializes in providing drug containment, delivery, and diagnostic solutions globally.
In the first quarter of 2025, Stevanato Group reported a revenue increase of 9% to €256.6 million, with high-value solutions comprising 43% of this total. The company’s gross profit margin rose by 80 basis points to 27.2%, and adjusted EBITDA margin improved by 100 basis points to 22.4%.
The Biopharmaceutical and Diagnostic Solutions (BDS) Segment led the growth with an 11% revenue increase, driven by high demand for high-value syringes and a partial recovery in EZ-fill vials. Conversely, the Engineering Segment saw a 4% revenue decline due to an unfavorable project mix. Despite this, the company maintained its revenue guidance for 2025, adjusting its EBITDA and EPS expectations to account for tariff impacts.
Stevanato Group’s strategic focus remains on expanding capacity at its facilities in Latina and Fishers to meet growing market demands. The company is confident in its ability to navigate tariff challenges through mitigation strategies and continues to prioritize completing legacy projects in Denmark.
Looking ahead, Stevanato Group is committed to achieving double-digit growth and expanding margins, driven by strong demand for its high-value solutions and ongoing improvements in its operational facilities. The company remains optimistic about its long-term objectives and shareholder value creation.